ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Waters Launches its Most Sensitive and Compact Clinical IVD System with Xevo TQ Absolute IVD Mass Spectrometer

News Summary:

  • Waters adds the Xevo TQ Absolute IVD System to its MassTrak IVD portfolio of LC-MS/MS systems, making it the most sensitive benchtop tandem quadrupole (TQ) mass spectrometer for clinical applications.i
  • Provides up to five times the sensitivity of instruments in its class,ii with lower detection limits for analyzing trace-level analytes in smaller sample volumes.
  • Its sustainable design is 45% smaller and uses 50% less nitrogen gas and electricity than comparable TQ-MS systems.iii

MSACL Conference 2023--Waters Corporation (NYSE: WAT) today unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230404005347/en/

Waters' newest MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (in dark grey), is up to five times more sensitive than similar commercial mass spectrometers for quantifying  analytes in samples of saliva, breath, and dried blood spots. (Photo: Business Wire)

Waters' newest MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (in dark grey), is up to five times more sensitive than similar commercial mass spectrometers for quantifying analytes in samples of saliva, breath, and dried blood spots. (Photo: Business Wire)

The powerful analytical performance of the Xevo TQ Absolute IVD mass spectrometer is up to five times more sensitive for quantifying clinical analytes than similar commercial instruments on the market. This sensitivity enables clinical laboratories to detect and measure trace level analytes within a sample at the lowest detection levels than previously possible.iv It can extend the testing capabilities of the clinical laboratory to include lower volume samples obtained in less-invasive assays such as saliva, breath, and dried blood spots. The system also enables clinical laboratories to expand their test menu to include multiplex panels and large molecules.

“Waters’ MassTrak IVD systems gives clinical diagnostic laboratories highly precise and flexible options that ultimately enable clinicians to provide better patient care,” said Jianqing Bennett, Waters Corporation Senior Vice President of the Waters Clinical Business Unit. “Adding the Xevo TQ Absolute IVD to the MassTrak IVD family offers customers class-leading sensitivity and analytical performance. Waters is uniquely positioned to enable clinical laboratories to develop reliable test methods for difficult analytes, helping them expand their capabilities to manage emerging remote sampling techniques.”

The new MassTrak LC-MS/MS IVD system includes the ACQUITY UPLC I-Class PLUS liquid chromatography instrument with the Xevo TQ Absolute IVD mass spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver rapid and accurate sample analysis to enhance the sensitivity of any mass spectrometer and simplify the characterization of the most complex sample. The Xevo TQ Absolute IVD System provides more consistent instrument-to-instrument performance, with a user-friendly design that maximizes service uptime. Its innovative design is also 45% smaller and uses 50% less nitrogen gas and electricity than comparable tandem quadrupole-mass spectrometry (TQ-MS) systems,v making it ideal for hospital labs and independent commercial labs with both sustainability and business growth goals to meet.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

___________________

i Waters comparison of TQ Absolute IVD vs. existing Waters TQ-XS IVD and the SCIEX 6500 IVD, which are the next two most sensitive IVD-compliant tandem quadrupole products currently available for commercial sale.

ii See endnote i above

iii Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495C, and Thermo TSQ Altis.

iv See endnote i above

v See endnote iii above

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.48
+0.81 (0.35%)
AAPL  277.51
+0.54 (0.19%)
AMD  212.52
+6.39 (3.10%)
BAC  52.90
+0.42 (0.79%)
GOOG  318.71
-4.93 (-1.52%)
META  635.94
-0.28 (-0.04%)
MSFT  484.31
+7.32 (1.53%)
NVDA  180.26
+2.44 (1.37%)
ORCL  207.65
+10.62 (5.39%)
TSLA  421.00
+1.60 (0.38%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.